Cindy Leissinger
Hematology & Oncology · New Orleans, LANPI 1700839933
Payments from drug & device makers
Across 183 payments — averaging $2362.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$140K
- Octapharma USA, Inc.$43K
- Sanofi US Services Inc.$39K
- Bio Products Laboratory USA, Inc.$33K
- Genentech, Inc.$30K
- CSL Behring$29K
- plus $118K from 26 others
What the payments were for
- Consulting fees$95,50471%
- Speaking & faculty fees$31,46523%
- Travel & lodging$4,7274%
- Food & beverage$3,2082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 25 | $140,098 |
| Octapharma USA, Inc. | 3 | $43,253 |
| Sanofi US Services Inc. | 7 | $39,027 |
| Bio Products Laboratory USA, Inc. | 2 | $32,875 |
| Genentech, Inc. | 5 | $29,584 |
| CSL Behring | 28 | $29,336 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $26,869 |
| Shire North American Group Inc | 28 | $23,568 |
| Bayer | 18 | $12,914 |
| Bioverativ Therapeutics Inc. | 2 | $10,592 |
| Global Blood Therapeutics, Inc. | 3 | $10,414 |
| Pfizer | 15 | $8,604 |
| Novo Nordisk AS | 3 | $7,200 |
| Dova Pharmaceuticals | 5 | $6,016 |
| Genentech USA, Inc. | 3 | $4,751 |
| Kedrion Biopharma Inc. | 1 | $2,600 |
| Chiesi USA, Inc. | 1 | $2,100 |
| Sanofi | 2 | $1,856 |
| EMD Serono, Inc. | 2 | $181 |
| Novartis | 4 | $84 |
| Merck | 4 | $74 |
| Novo Nordisk | 1 | $69 |
| Astellas Pharma US Inc | 2 | $47 |
| HEMA Biologics, LLC | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $28 |
| AbbVie | 1 | $23 |
| AstraZeneca | 1 | $21 |
| Spark Therapeutics, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$432,302 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 24 | $5,053 |
| Tranexamic Acid | 18 | $1,626 |
| Fondaparinux Sodium | 14 | $1,399 |
| Hydroxyurea | 22 | $363 |
| Warfarin Sodium | 48 | $294 |
| Deferasirox | 11 | $240 |
| Celecoxib | 14 | $145 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Orleans
- Marc MatranaNew Orleans$4.6M
- Pedro BarataNew Orleans$4.2M
- Carter DavisNew Orleans$1.6M
- Maissaa JanbainNew Orleans$1.5M
- Lingling duNew Orleans$1.2M
- John ColeNew Orleans$896K
- Furhan YunusNew Orleans$422K
- David MorrisonNew Orleans$313K
- Stefan GrantNew Orleans$261K
- Michelle LochNew Orleans$232K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.